Evidence map›Paper›PMID 39735644›Full record

ArticleFrontiers in endocrinology2024

Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment.

J S Saavedra T, Humberto Alejandro Nati-Castillo, L A Valderrama Cometa, Wilfredo A Rivera-Martínez, Josué Asprilla, C M Castaño-Giraldo, Leonardo Sánchez S, Mishell Heredia-Espín, Marlon Arias-Intriago, Juan S Izquierdo-Condoy

Registry-linked trialAbstract readScoping Review
In one paragraph

Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07538791 (Italian Multicenter Experience With Radioreceptor-assisted Therapy), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07538791 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT) in Pheochromocytomas and Paragangliomas: a Retrospective Analysis

TypeobservationalSponsorAzienda USL Reggio Emilia - IRCCSRan2026 to 2028Enrolled210ConditionsPheochromocytomas, ParagangliomasArmsPeptide Receptor Radionuclide Therapy (PRRT)
3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Correlation ofDiagnostics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Review
  4. Pheochromocytomas and Paragangliomas.Endocrinology and metabolism clinics of North America · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

J S Saavedra TFamily Medicine Department, Universidad Javeriana, Cali, Colombia.
Humberto Alejandro Nati-CastilloInterinstitutional Group on Internal Medicine (GIMI 1), Department of Internal Medicine, Universidad Libre, Cali, Colombia.
L A Valderrama CometaOrgan and Tissue Transplant Unit, Clínica Imbanaco, Cali, Colombia.
Wilfredo A Rivera-MartínezFacultad de Medicina, Universidad de Antioquia, Medellin, Colombia.
Josué AsprillaDivision of Pathology, Clínica Imbanaco, Grupo Quirónsalud, Cali, Colombia.
C M Castaño-GiraldoFacultad de ciencias de la Salud, Universidad del Quindío, Armenia, Colombia.
Leonardo Sánchez SOne Health Research Group, Universidad de las Americas, Quito, Ecuador.
Mishell Heredia-EspínOne Health Research Group, Universidad de las Americas, Quito, Ecuador.
Marlon Arias-IntriagoOne Health Research Group, Universidad de las Americas, Quito, Ecuador.
Juan S Izquierdo-CondoyOne Health Research Group, Universidad de las Americas, Quito, Ecuador.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors derived from chromaffin cells, with 80-85% originating in the adrenal medulla and 15-20% from extra-adrenal chromaffin tissues (paragangliomas). Approximately 30-40% of PPGLs have a hereditary component, making them one of the most genetically predisposed tumor types. Recent advances in genetic research have classified PPGLs into three molecular clusters: pseudohypoxia-related, kinase-signaling, and

Indexed as

Adrenal Gland NeoplasmsPheochromocytomaDisease ManagementHumansParagangliomadiagnosishormonal imbalancemanagementparagangliomapheochromocytomatreatment

Identifiers

PMID39735644
PMCPMC11671257

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.